Stocktoria
Astrana Health, Inc. ASTH
Astrana Health, Inc. (ASTH) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 0.36% (safety: safe). FY2025 revenue was $3.2B at a 0.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.112 |
| Retained earnings / assets | 0.139 |
| EBIT / assets | 0.035 |
| Equity / liabilities | 0.478 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ASTH | Astrana Health, Inc. | 3/9 | 1.93 | 98.1 | +56.4% |
| FCN | FTI CONSULTING, INC | 5/9 | 4.54 | 16.8 | +2.4% |
| ICFI | ICF International, Inc. | 6/9 | 3.41 | 14.1 | -7.3% |
| HURN | Huron Consulting Group Inc. | 4/9 | 2.98 | 15.2 | +11.7% |
| G | Genpact LTD | 5/9 | 3.63 | 8.8 | +6.6% |
| ONT | Onterris, Inc. | 4/9 | 0.55 | — | +19.3% |
| RMR | RMR GROUP INC. | 3/9 | 4.47 | 38.1 | -22% |
About Astrana Health, Inc.
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.
FAQ
Is ASTH financially healthy?
Astrana Health, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does ASTH pay a dividend, and is it safe?
Yes. Astrana Health, Inc. pays a dividend yielding about 0.36% with a 35.1% payout ratio, rated “safe” for safety.
How profitable is ASTH?
In FY2025, Astrana Health, Inc. had a net margin of 0.7% and a return on equity of 2.8%.
Is ASTH overvalued or undervalued?
Astrana Health, Inc. trades at about 77.8× trailing earnings — above its 10-year norm (10-year range 20.3×–67.3×, median 36.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ASTH?
The average Wall-Street price target for Astrana Health, Inc. is $46.00, about 28.5% above the recent price, from 9 analysts.
Is ASTH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Astrana Health, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone, a P/E of about 98.1×, a dividend yield of 0.36%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.